PODCAST

AXIS Medical Education

ReachMD

science & medicine medicine

All Episodes

00:00:00

Chairperson's Perspective: Redefining Treatment...

AXIS Medical Education ·

2024/09/30

Host: Sara M. Tolaney, MD, MPH This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to

00:00:00

Chairperson Perspective: Precision Payloads:...

AXIS Medical Education ·

2024/07/19

Host: Joshua E. Reuss, MD Alterations in ERBB2, the gene encoding HER2, have been recognized as drivers in the development of NSCLC. Therefore, HER2 is an actionable biomarker that has emerged in NSCLC diagnosis and treatment. HER2 mutations activate the HER2 signaling pathway, which facilitates oncogenic transformation and increases tumor proliferation. Although practice guidelines recommend molecular testing to identify alterations, the interpretation of tests and application of

00:00:00

CD20 X CD3 Bispecifics—Redefining Treatment for...

AXIS Medical Education ·

2024/05/31

Host: Matthew Lunning, DO, FACP In the rapidly evolving landscape of treating patients with relapsed or refractory large/diffuse large B-cell lymphoma (R/R LBCL/DLBCL), recent advancements are providing newfound hope. Immunochemotherapy with R-CHOP has long been the standard first-line treatment, but a significant portion of patients experience relapses and refractory disease. Until recently, salvage chemotherapy followed by autologous stem cell transplant (ASCT) was the only curative

00:00:00

Improving Interprofessional Management and Clinical...

AXIS Medical Education ·

2024/02/28

Guest: Kathleen Moore, MD, MS The establishment of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as an effective therapeutic strategy in ovarian cancer has been made possible through a deepened understanding of the impact of mutations in DNA damage response pathways on tumorigenesis. The success of this approach has led to the regulatory approval of PARP inhibitors for the treatment of patients with advanced ovarian cancer. PARP inhibitors as first-line

00:00:00

Expert Answers to Common Questions for Improving the...

AXIS Medical Education ·

2024/01/29

Guest: Caron A. Jacobson, MDCD19-directed chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment of aggressive non-Hodgkin lymphoma (NHL), offering patients with refractory/relapsed disease the chance for a potential cure after a single infusion. However, the widespread use of CAR T-cell therapies faces several challenges, from the production of the therapies to the management of toxicities to issues of inpatient vs outpatient administration. While CAR

00:00:00

Chairperson’s Perspective: CDK 4/6 Inhibitors:...

AXIS Medical Education ·

2023/12/31

Guest: Joyce O'Shaughnessy, MD By 2040, the global breast cancer burden is expected to increase by 40%, resulting in more than 3 million new cases and 1 million deaths per year. Approximately 65% of cases among women less than 50 years of age and 75% of cases among women over 50 years of age are classified as HR+/HER2-. Although endocrine therapy is employed as standard-of-care treatment for many patients with HR+/HER2- breast cancer, not all such patients respond to endocrine

00:00:00

Taking Command of the Treatment of ESA-Refractory,...

AXIS Medical Education ·

2023/07/07

Host: Paul P. Doghramji, MD, FAAFP Guest: Rami Komrokji, MD Guest: Allan Platt, PA-C, MMSc Low-risk myelodysplastic syndrome (LR-MDS) is an acquired bone marrow disorder that manifests with symptomatic anemia. Many patients become dependent on red blood cell transfusions. Erythropoiesis-stimulating agents (ESAs) are the first-line treatment, but not all patients with LR-MDS respond to ESAs, and many become refractory to ESAs over time. Although advances have been made in the

00:00:00

NSCLC Therapy Management and Biomarker Testing

AXIS Medical Education ·

2023/06/30

Host: Mark Socinski, MD Capitalizing on the advances in the identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapies are the current standard of care for eligible patients with advanced non–small cell lung cancer (NSCLC). Many targeted therapies are approved for the treatment of metastatic NSCLC with oncologic therapy decisions based on the presence of mutations and gene rearrangements. The National

00:00:00

Getting on Board with Real-World Evidence About CDK...

AXIS Medical Education ·

2023/03/30

Host: Richard S. Finn, MD Evidence supports the notion that adding targeted agents that have a different mechanism of action than those that cause estrogen receptor interference can improve the benefits and outcomes seen with endocrine therapies alone in HR+/HER2- metastatic breast cancer (mBC). Clinical trial and real-world evidence show that CDK 4/6 inhibitors are safe and effective treatments for HR+/HER2- mBC. Real-world evidence can supplement clinical trial evidence and be more

9 results

AXIS Medical Education

All Episodes

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe